<DOC>
	<DOC>NCT02061761</DOC>
	<brief_summary>The purpose of this study is to characterize the safety, tolerability and maximum tolerated dose of BMS-986016 administered alone or in combination with Nivolumab to subjects with relapsed hematologic malignancies.</brief_summary>
	<brief_title>Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com For dose escalation monotherapy: CLL, HL, NHL, MM For dose expansion monotherapy: CLL, HL, NHL For dose escalation and dose expansion in combination with BMS936558: HL and DLBCL Progressed, or been intolerant to, at least one standard treatment regimen Not eligible for or declined transplantation or any standard therapy known to be life prolonging or life saving Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 At least 1 lesion with measurable disease at baseline Availability of an existing tumor biopsy sample (or consent to allow pretreatment tumor biopsy if sample not available) Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease (controlled CNS metastases are allowed) Autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>